Register for our free email digests:
U3 Pharma AG
Division of Daiichi Sankyo Co. Ltd.
Latest From U3 Pharma AG
Daiichi Sankyo's decision to close an R&D facility in India has drawn mixed responses from the local industry, coming as it does against the backdrop of the Japanese firm’s disastrous acquisition of Ranbaxy.
Daiichi Sankyo has unveiled disappointing results for one pipeline molecule that has now been suspended for lung cancer, but has gained another for breast cancer as it continues to develop its oncology portfolio.
"I love it when a plan comes together," Hannibal Smith of TV show The A-Team used to say, a catchphrase which Daiichi Sankyo will be hoping is appropriate in around five years' time as it looks back on the results of its new mid-term strategy.
Following the European approval of Lixiana last year, Daiichi Sankyo has tapped Merck & Co to maximize regional sales of the novel anticoagulant in markets where it has limited reach, but will face multiple competitors.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Daiichi Sankyo Co. Ltd.
- Senior Management
Irina Staatz-Granzer, PhD, CEO
Mike Rothe, PhD, CSO
- Contact Info
U3 Pharma AG
Phone: (49) 89 8103 90
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.